CN106420840A - Application of Clostridium butyricum in preparation of preparations for preventing or treating depression - Google Patents
Application of Clostridium butyricum in preparation of preparations for preventing or treating depression Download PDFInfo
- Publication number
- CN106420840A CN106420840A CN201611037515.4A CN201611037515A CN106420840A CN 106420840 A CN106420840 A CN 106420840A CN 201611037515 A CN201611037515 A CN 201611037515A CN 106420840 A CN106420840 A CN 106420840A
- Authority
- CN
- China
- Prior art keywords
- clostridium butyricum
- cfu
- preparation
- bifidobacterium
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses application of Clostridium butyricum in the preparation of preparations for preventing or treating depression, and particularly relates to the application of the Clostridium butyricum in depression preventing or treating and depressive symptom relieving.
Description
Technical field
The present invention relates to application in preparation prevention or treatment depression preparation for the clostridium butyricum, specifically use clostridium butyricum
Prevention or treatment depression, reduce depressive symptom.
Background technology
Depression complicated mechanism, clinical syndrome is various, and course of disease length, easily recurrence.Depression betide world community,
In the crowd of all orders of society and various cultural environment.With social development, the increasing of stressor, the incidence of disease is also in increase year by year
Trend.The World Health Organization (WHO) predicts, the disease that will become developing country's most serious to the year two thousand twenty depression is born
Carry on a shoulder pole, severe depression can become dead and disabled second largest reason when the time comes.
During what huge life and work pressure led to mostly be, major depressive disorder, simple psychotherapy can not reach ideal
Clinical efficacy.Therefore clinical in addition to giving the necessary comfort of patient, dredging, instruct, rely primarily on medicine to control, main medicine
Thing includes tricyclic antidepressant, tetracyclic antidepressants etc..Existing medicine antidepression spectrum is narrow, toxic and side effect is big, have habituation
Property and the defect such as contraindication, severely impacted treatment and the compliance of clinic.Chinese medicine few side effects are in Western medicine, but curative effect is delayed
Slowly.And the traditional Chinese medical science controls standard for the objective complete parting opinion generally acknowledged of diagnosis and treatment still neither one of depression, how
Systematic difference traditional Chinese medical herbal treatment depression need to study further.
Therefore, searching can effectively prevent or treat depression, reduce depressive symptom, and safety does not have any toxic and side effect
Medicine be clinical in the urgent need to.The present inventor finds through research, and clostridium butyricum can effectively prevent or treat depression,
Safety does not have any toxic and side effect, and effect is better than Bifidobacterium, and has no that correlative study is reported, special this patent of invention of application.
Content of the invention
It is an object of the invention to provide a kind of energy prevents or treats the preparation of depression, said preparation is made up of clostridium butyricum.
The preparation of the preparation of the present invention is implemented preferably through following step, but is not limited to this preparation technology, known
The preparation technology enabling all permissible：Take the sample that may contain clostridium butyricum, then sample be placed in sterilizing anaerobism bottle,
It is blown into nitrogen to be sufficiently mixed simultaneously, therefrom take rapidly 2 grams of samples to add in the dilution of 18mL sterilizing, be blown into nitrogen simultaneously abundant
Mix, in aseptic operating platform, carry out 10-1、10-2、10-3、10-4, 10-5, 10-6, 10-7Gradient dilution, takes 10-5, 10-6, 10-7
Three dilution gradients, are respectively coated on clostridium butyricum selectivity single bacterium colony separation solid medium, are placed in anaerobic jar, anaerobism
Cultivate 48 hours at 37 DEG C, select the single bacterium colony growing fine to be inoculated in respectively in liquid amplification culture medium, be placed in anaerobic jar,
Amplification cultivation 48 hours at 37 DEG C of anaerobism.Gained medium centrifugal (12000rpm) is isolated after thalline, will be true for thalline freezing
Empty dry, modulate and bacterium powder is dried, then carry out strain idenfication, product butyric acid is tested, enteron aisle is colonized experiment and toxicity test for a long time,
Butyric acid can be produced and avirulent clostridium butyricum is dried bacterium powder desired proportions interpolation auxiliary material and makes tablet, capsule, powder, powder
The various formulation such as agent or liquid preparation, also can add the compound sugar such as other viable bacterias or FOS to play synergy.
Clostridium butyricum selectivity single bacterium colony separation solid medium is preferably but not limited to：Purified water 1L, peptone
40.0g, Na2HPO45.0g, K2HPO41.0g, NaCl 2.0g, MgSO40.1g, glucose 2.0g, agar 25.0g, adjust pH
7.6,116 DEG C sterilize 20 minutes, treat that it is cooled to 50 DEG C about, add yolk liquid 50.0mL, add final concentration of 200 μ g/mL's
Aerosporin, adds the neomycin of final concentration 200 μ g/mL, after fully mixing, dispensing is in plate.
Clostridium butyricum liquid amplification culture medium is preferably but not limited to：Purified water 1L, tryptone 10.0g, beef extract
10.0g, yeast extract 3.0g, glucose 5.0g, NaCl 5.0g, soluble starch 1.0g, cysteine hydrochloride 0.5g, vinegar
Sour sodium 3.0g, agar 0.5g, adjust pH 6.6-7.0,121 DEG C, sterilize 15 minutes.
For being further elaborated with the present invention, inventor utilizes said method to separate by clostridium butyricum selectivity single bacterium colony
Solid medium separates and identifies avirulent clostridium butyricum, and clostridium butyricum of the present invention is not limited to this is described
Bright described bacterium, as long as avirulent clostridium butyricum is all of the present invention, all within the scope of the present invention.
Clostridium butyricum of the present invention is preferably but not limited to clostridium butyricum DF96101 deposit number CGMCC 0313.1 or fourth
Sour clostridium QA-08 deposit number CGMCC 2303.
The bacteriological quality of the clostridium butyricum that the present invention preferably uses in implementing to illustrate：
1st, to illustrate the invention, the present invention utilizes the detached clostridium butyricum of said method is clostridium butyricum DF96101 preservation
Numbering CGMCC 0313.1 or clostridium butyricum QA-08 deposit number CGMCC 2303.
2nd, colonial morphology
Micro- sem observation：Long 3.0-6.0 micron, wide 0.6-1.2 micron, straight-bar or fusiform bacterium, Gram-positive, produce
Gemma, spore owes end life.
Plate morphology：Bacterium colony is circular, and edge is irregular, and slightly convex, opaque, color is yellowish, mattness.
3rd, Physiology and biochemistry identification
Hydrogen sulfide:-；Indoles:-；Gelatin liquefaction:-；Ammonia:-；Nitrate reduction:-；Nagler's reaction:-；Urase:-；V-
P tests:-；Catalase:-；Whether aerobic:Anaerobic.
4th, glycolysis experimental identification
Arabinose:+；Rhamnose:+；Cellobiose:+；D-glucitol:-；D-Fructose:+；Soluble starch:+；D- half
Lactose:+；Sucrose:+；Glucose:+；Trehalose:+；Synanthrin:+；Wood sugar:+；Lactose:+；Gluconate (sodium):+；D (+) sweet
Dew sugar:+；Maltose:+；PEARLITOL 25C:+；Glycerine:+；D (+) raffinose:+；Ribose:+；Melezitose:+；Melibiose:+.
Clostridium butyricum of the present invention refers to the bion of work.
The present invention be using effective dose as stated above detached clostridium butyricum as main active ingredient, according to certain
Preparation process, adds conventional excipient, flavor enhancement, disintegrant, preservative, lubricant, wetting agent, binder, solvent, thickening
The auxiliary materials such as agent, solubilizer, make any fit for service formulation, such as tablet, capsule, granule, powder, liquid system
The formulations such as agent, pulvis.
Clostridium butyricum of the present invention makes active bacteria formulation as key agents active ingredient.
Indication effective dose of the present invention refer to as stated above detached clostridium butyricum according to described above alone or in combination
The total viable count comprising as the solid live bacteria preparation that key agents active ingredient is made cannot be below 1 × 106CFU/g, typically
1 × 107More than CFU/g, can reach 1 × 1012CFU/g or 1 × 1012More than CFU/g.
Indication effective dose of the present invention refer to as stated above detached clostridium butyricum according to described above alone or in combination
The total viable count comprising as the liquid active bacteria formulation that key agents active ingredient is made cannot be below 1 × 106CFU/mL, typically
1 × 107More than CFU/mL, can reach 1 × 1012CFU/mL or 1 × 1012More than CFU/mL.
Preparation of the present invention include clostridium butyricum be used alone or with other drugs use in conjunction, especially include butyric acid shuttle
Bacterium be used alone or with Bifidobacterium use in conjunction.
Bifidobacterium of the present invention refers to the bion of work.
In the preparation of Bifidobacterium use in conjunction of the present invention, the total viable count of Bifidobacterium that solid pharmaceutical preparation comprises is not low
In 1 × 106CFU/g, typically 1 × 107More than CFU/g, can reach 1 × 1012CFU/g or 1 × 1012More than CFU/g；Or
The total viable count of Bifidobacterium that liquid preparation comprises is not less than 1 × 106CFU/mL, typically 1 × 107More than CFU/mL, highest can
Reach 1 × 1012CFU/mL or 1 × 1012More than CFU/mL.
Due to present invention firstly discloses clostridium butyricum makes preparation in prevention or treatment depression as main active ingredient
Application in disease, the preparation therefore containing above-mentioned clostridium butyricum is preventing or is treating the application in depression preparation to belong to the present invention
Protection domain.
Clostridium butyricum of the present invention, when making any formulation, is respectively provided with prevention or the work for the treatment of depression
With.If being prepared into preparation containing clostridium butyricum composition in its component, in the mark such as its packaging or specification or at other
As long as on any propaganda material indicate or prompting have prevention or treatment depression effect, then fall into protection scope of the present invention it
Interior.
Clostridium butyricum of the present invention can make medicine, health food, food or drink etc..
Specific embodiment
Preparation example explanation：The above-mentioned preparation to clostridium butyricum preparation illustrates, here by clostridium butyricum
It is specifically described as a example DF96101 deposit number CGMCC 0313.1 or clostridium butyricum QA-08 deposit number CGMCC 2303,
Preparation method those skilled in the art of other clostridium butyricum bacterial classification preparations are easy to grasp by the present embodiment, other formulations
Preparation method those skilled in the art are easy to grasp by this enforcement, and here no longer describes explanation one by one.Preparation method is not
It is confined to described in the embodiment of the present invention, the known method that can reach preparation purpose is all permissible, and the preparation of embodiment explanation is only
It is the description of the invention, be not limiting the scope of the invention.
The preparation of preparation embodiment 1 clostridium butyricum pulvis
The preparation of 1 bacterium powder and the identification of bacterial classification
Take the fecal specimens of people, then sample is placed in sterilizing anaerobism bottle, is blown into nitrogen and is sufficiently mixed simultaneously, rapidly
Therefrom take 2 grams of samples to add in the dilution of 18mL sterilizing, be blown into nitrogen and fully mix simultaneously, in aseptic operating platform, carry out
10-1、10-2、10-3、10-4, 10-5, 10- 6, 10-7Gradient dilution, takes 10-5, 10-6, 10-7Three dilution gradients, are respectively coated in junket
On sour clostridium selectivity single bacterium colony separation solid medium, it is placed in anaerobic jar, cultivates 48 hours at 37 DEG C of anaerobism, select growing way
Good single bacterium colony is inoculated in liquid amplification culture medium respectively, is placed in anaerobic jar, amplification cultivation 48 hours at 37 DEG C of anaerobism.
Gained medium centrifugal (12000rpm) is isolated after thalline, thalline vacuum freezedrying modulates and bacterium powder is dried, then
Carry out strain idenfication, be accredited as clostridium butyricum through Physiology and biochemistry and product butyric acid experimental analysis, be that clostridium butyricum DF96101 preservation is compiled
Number CGMCC 0313.1 or clostridium butyricum QA-08 deposit number CGMCC 2303.
Clostridium butyricum DF96101 deposit number CGMCC 0313.1 or clostridium butyricum QA-08 deposit number CGMCC 2303
Prepared by bacterium powder, by clostridium butyricum DF96101 deposit number CGMCC 0313.1 or clostridium butyricum QA-08 deposit number CGMCC
2303 are inoculated in clostridium butyricum liquid amplification culture medium, amplification cultivation 48 hours at 37 DEG C of anaerobism.By gained medium centrifugal
(12000rpm) after isolating thalline, by thalline vacuum freezedrying, modulate and bacterium powder is dried, viable count is 1 × 109CFU/
More than g.
2 toxicity tests
2.1 animals and packet take 30 SPF rank mouse, 6-8 week old, body weight 14-18g, are randomized into clostridium butyricum
0313.1 group of CGMCC, 2303 groups of clostridium butyricum CGMCC and non-administered group, every group 10.
Above-mentioned different clostridium butyricum bacterium powder is modulated to be 1 containing bacterium number with purified water by 2.2 preparation bacterium solution respectively ×
109The bacterium solution of CFU/mL.
2.3 methods each clostridium butyricum group and non-administered group all give identical basal feed, and rearing conditions are all consistent,
Each clostridium butyricum group gavages clostridium butyricum bacterium solution 0.5mL daily, and non-administered group gavages purified water 0.5mL daily, feeds 14 days, sees
Examine body weight and toxic reaction.
2.4 result
All abnormal conditions in each group mouse, does not occur chatter, spasm, ataxia, attitude abnormal, no eyeball is dashed forward
Go out, urinate normal, skin, breathing are normal, no death condition has no toxic reaction.
3 are prepared into the formulations such as pulvis
Separated with method after identification according to above-mentioned steps, through experimental check nontoxicity so that it may make clostridium butyricum bacterial classification
Bacterium powder, then according to needing interpolation relevant auxiliary materials to make various formulations, preferably according to the viable count of clostridium butyricum bacterium powder, adds in proportion
Plus starch makes pulvis, viable count is made to be not less than 1 × 107CFU/g, then packs.
Application effect embodiment explanation：
The present invention is with clostridium butyricum DF96101 deposit number CGMCC 0313.1 or clostridium butyricum QA-08 deposit number
CGMCC 2303 illustrates the application effect of clostridium butyricum for representative, and bacterium powder is provided by Qingdao DongHai Pharmacy Co., Ltd.The present invention
Used in Bifidobacterium be buy gained, the bifidobacteria viable bacteria that the public can buy.
Application effect embodiment 1：Application in treatment depression for the clostridium butyricum
1 model group preparation：
1.1 animals used as test choose adult male SD rats, and (body weight 200-220g, purchased from dimension tonneau China animal used as test
The heart), adapt to before experiment raise one week：Natural lighting, 22 ± 2 DEG C of room temperature, freely absorb food and water, daily timing is changed and raised
Material, well-ventilated, exclusion other stress factor interference.
1.2 preparation methods adopt chronic not it is contemplated that gently stress processing method, for above-mentioned adaptation raise experiment
Animal takes following 10 kinds of Coping styles to be processed：Fasting 24h, prohibit water 24h, folder tail (at rat root of the tail portion 1cm) 5min,
Overturn round the clock 24h, 4 DEG C of cold-wate swimming 5min, 45 DEG C of environment 5min, moist bedding and padding 24h, tilt 45 degree 24h, behavior fetters 4h,
Level shakes 60 times/min 45min.Above-mentioned 10 kinds method stress carry out random process in 28 days, take a kind of method daily,
Identical stimulation can not continuously occur and at least be spaced more than 7 days, set up Depression in Rats model.
2 drug therapy experiments：
The method that 2.1 experimental techniques press 1.1 adapts to raise adult male SD rats one week, and rat is randomly divided into 6 groups
(n=10)：Clostridium butyricum (DF96101) treatment group, clostridium butyricum (QA-08) treatment group, Bifidobacterium treatment group, Prozac are controlled
Treatment group, model control group, Normal group.Each treatment group and control group all give identical basal feed, and rearing conditions are equal
Unanimously, clostridium butyricum (DF96101, QA-08) and the use of Bifidobacterium treatment group are 1 × 10 containing bacterium number6CFU/mL (uses 0.9%
Physiological saline modulate bacterium powder) bacterium solution gavage 0.5mL, Fluoxetine in Treatment group use 0.2g/kg liquid (use 0.9% physiology salt
Water is modulated to the liquid of 0.2mg/mL) gavage 0.5mL, control group group gavages 0.9% physiological saline 0.5mL daily.Using 1.2 institutes
State Chronic unpredictable stress method and set up rat chronic Stress Depression Model, and carry out a medicine before each modeling
Intervene, comparative drug intervention changes to the behaviouristics of the gentle Stress model rat of chronic not predictability.
2.2 pharmaceutical intervention are to chronic not it is contemplated that surveying respectively before and after the Behavior evaluation experiment of gentle Stress model rat
Determine the body weight of rat, experiment carries out Behavior evaluation after terminating, real including spacious field experiment, forced swim test and syrup preference
Test.Data carries out statistical analysis using SPSS 21.0.
3 results
3.1 pharmaceutical intervention chronic not it is contemplated that after gentle Stress model rat changes of weight
After clostridium butyricum DF96101 intervenes, rat body weight is 399.65 ± 10.18g, and after QA-08 intervenes, rat body weight is
401.26 ± 10.82g, no significant difference (P ＞ 0.05) between the two, and Fluoxetine in Treatment group (389.63 ± 22.91g) between
Also no significant difference (P ＞ 0.05), extremely significantly raises (P ＜ 0.01) compared with model group (325.16 ± 17.70g).Butyric acid shuttle
After bacterium DF96101 and QA-08 intervenes, rat body weight is all remarkably higher than Bifidobacterium treatment group (376.76 ± 12.22g) (P ＜
0.05).Clostridium butyricum is to rat chronic not it is contemplated that gently the increase of body weight afterwards stress have significant curative effect, its body weight evolution is high
In Fluoxetine in Treatment group, and it is significantly higher than Bifidobacterium treatment group.It is shown in Table 1.
Table 1 pharmaceutical intervention chronic not it is contemplated that after Stress model rat body weight change statistical analysis (x ± s)
| Packet | Number of cases (n) | Body weight (g) |
| Clostridium butyricum (DF96101) treatment group | 10 | 399.65±10.18 |
| Clostridium butyricum (QA-08) treatment group | 10 | 401.26±10.82 |
| Bifidobacterium treatment group | 10 | 376.76±12.22 |
| Fluoxetine in Treatment group | 10 | 389.63±22.91 |
| Model control group | 10 | 325.16±17.70 |
| Normal group | 10 | 439.88±11.57 |
3.2 pharmaceutical intervention chronic not it is contemplated that after gentle Stress model rat behaviouristics change
The spacious field traversing times of rat, upright number of times, reason hair number of times and mould after clostridium butyricum DF96101 and QA-08 intervention
Type group is compared all pole and is significantly improved (P ＜ 0.01), and the forced swimming dead time all extremely significantly shortens (P ＜ 0.01), syrup preference
Property all pole significantly improves (P ＜ 0.01), between the two no significant difference (P ＞ 0.05), and no aobvious and Fluoxetine in Treatment group between
Write difference (P ＞ 0.05)；Clostridium butyricum DF96101 with QA-08 compared with Bifidobacterium, after intervention, pass through time by the spacious field of rat
Several, upright number of times, reason hair number of times are significantly increased (P ＜ 0.05), and the forced swimming dead time all significantly shortens (P ＜ 0.05),
Syrup Preference is significantly increased (P ＜ 0.05).Rat chronic not it is contemplated that gently stress after, clostridium butyricum intervention can significantly subtract
The Depressive behavior of few rat, its effect is significant is better than between Bifidobacterium, and Prozac no significant difference.It is shown in Table 2.
Table 2 pharmaceutical intervention chronic not it is contemplated that after Stress model rat behavior change statistical analysis (x ± s)
4 discussion
Chronic not it is contemplated that the body weight that gentle Stress model group compares rat with Normal group substantially reduces, and medicine is done
Organize in advance and compare the body weight of rat with model group and all substantially rise, wherein the evident in efficacy of clostridium butyricum treatment group is better than Bifidobacterium
Treatment group, and it is better than Fluoxetine in Treatment group.Show that depression can lead to organism metabolic disorder thus leading to Body weight loss, clostridium butyricum
Intervention can significantly recover the body weight that rat reduces because depressed.Bonding behavior assessment result shows, after clostridium butyricum is intervened, slowly
Property not it is contemplated that the Depressive behavior that gently stress occur is significantly improved, its effect be substantially better than Bifidobacterium treatment
Group, and intervene retarded depression symptom improvement no significant difference with Fluoxetine in Treatment group.Show clostridium butyricum as main active
The antidepressant effect consistent with Prozac effect can be reached, thus providing new solution party for the treatment and prevention of depression
Method.
Clostridium butyricum preparation can effectively prevent or treat depression hence it is evident that reducing depressive symptom, and the secondary work of no any poison
With application compliance is good, is to prevent or treat the new method of depression, new breakthrough.
Clostridium butyricum bacterial classification used in implementation process for the present invention is respectively on July 28th, 1997 and 2007 12
The moon 26 is in China Committee for Culture Collection of Microorganisms's common micro-organisms center (Datun Road, Chaoyang District, Beijing City, Chinese section
Institute of microbiology of institute, postcode 100101) preservation, totally two following bacterial classifications, but clostridium butyricum of the present invention is simultaneously
It is not limited to both microorganism fungus kinds.
(1) Classification And Nomenclature：Clostridium butyricum Clostridium butyricum, preserves numbering 0313.1.
(2) Classification And Nomenclature：Clostridium butyricum Clostridium butyricum, preserves numbering 2303.
Above-mentioned two bacterial classification is survival through this microorganism Spot detection, testing result.
Bifidobacterium used in implementation process for the present invention comes from commercial channel, belongs to purchase gained.
Claims (10)
1. application in preparation prevention or treatment depression preparation for the clostridium butyricum.
2. as described in claim 1 application it is characterised in that described preparation includes clostridium butyricum is used alone or and other drugs
Use in conjunction.
3. apply it is characterised in that described preparation includes medicine, health food, food, drink as described in claim 1.
4. apply as described in claim 1 it is characterised in that described clostridium butyricum refers to the bion of work.
5. apply it is characterised in that described clostridium butyricum includes clostridium butyricum DF96101 deposit number as described in claim 1
CGMCC 0313.1 or clostridium butyricum QA-08 deposit number CGMCC 2303.
6. as described in claim 2 application it is characterised in that described preparation includes clostridium butyricum is used alone or and Bifidobacterium
Use in conjunction.
7. apply as described in claim 6 it is characterised in that described Bifidobacterium refers to the bion of work.
8. as described in claim 1, application, it is characterised in that prevention or treatment depression, reduces depressive symptom.
9. as described in claim 1 preparation it is characterised in that the total viable count of clostridium butyricum that solid pharmaceutical preparation comprises be not less than 1 ×
106CFU/g, typically 1 × 107More than CFU/g, can reach 1 × 1012CFU/g or 1 × 1012More than CFU/g；Or liquid
The total viable count of clostridium butyricum that preparation comprises is not less than 1 × 106CFU/mL, typically 1 × 107More than CFU/mL, can reach
1×1012CFU/mL or 1 × 1012More than CFU/mL.
10. as described in claim 6 preparation it is characterised in that the total viable count of Bifidobacterium that solid pharmaceutical preparation comprises be not less than 1 ×
106CFU/g, typically 1 × 107More than CFU/g, can reach 1 × 1012CFU/g or 1 × 1012More than CFU/g；Or liquid
The total viable count of Bifidobacterium that preparation comprises is not less than 1 × 106CFU/mL, typically 1 × 107More than CFU/mL, can reach
1×1012CFU/mL or 1 × 1012More than CFU/mL.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611037515.4A CN106420840A (en) | 2016-11-23 | 2016-11-23 | Application of Clostridium butyricum in preparation of preparations for preventing or treating depression |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611037515.4A CN106420840A (en) | 2016-11-23 | 2016-11-23 | Application of Clostridium butyricum in preparation of preparations for preventing or treating depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106420840A true CN106420840A (en) | 2017-02-22 |
Family
ID=58221268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611037515.4A Pending CN106420840A (en) | 2016-11-23 | 2016-11-23 | Application of Clostridium butyricum in preparation of preparations for preventing or treating depression |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106420840A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107095885A (en) * | 2017-04-28 | 2017-08-29 | 青岛东海药业有限公司 | Application of the clostridium butyricum in prevention or treatment COPD preparation is prepared |
| CN107115362A (en) * | 2017-04-28 | 2017-09-01 | 青岛东海药业有限公司 | Application of the bacillus coagulans in prevention or treatment bronchial astehma preparation is prepared |
| CN107137428A (en) * | 2017-06-05 | 2017-09-08 | 青岛东海药业有限公司 | Application of the clostridium butyricum in prevention or treatment chronic fatigue syndrome preparation is prepared |
| CN110592248A (en) * | 2019-10-25 | 2019-12-20 | 江南大学 | Method for efficiently identifying/screening clostridium butyricum and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101095698A (en) * | 2006-06-26 | 2008-01-02 | 青岛东海药业有限公司 | Probiotics and prebiotics for preventing and treating foetid faeces and foetid faeces poisoning syndrome and the composition preparations thereof |
| US20130142776A1 (en) * | 2003-10-29 | 2013-06-06 | Allergan, Inc. | Botulinum toxin treatments of depression |
| CN105012349A (en) * | 2015-08-06 | 2015-11-04 | 温州医科大学 | Probiotic preparation for preventing and treating vascular dementia and preparation method of probiotic preparation |
-
2016
- 2016-11-23 CN CN201611037515.4A patent/CN106420840A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130142776A1 (en) * | 2003-10-29 | 2013-06-06 | Allergan, Inc. | Botulinum toxin treatments of depression |
| CN101095698A (en) * | 2006-06-26 | 2008-01-02 | 青岛东海药业有限公司 | Probiotics and prebiotics for preventing and treating foetid faeces and foetid faeces poisoning syndrome and the composition preparations thereof |
| CN105012349A (en) * | 2015-08-06 | 2015-11-04 | 温州医科大学 | Probiotic preparation for preventing and treating vascular dementia and preparation method of probiotic preparation |
Non-Patent Citations (1)
| Title |
|---|
| FANG-YAN WANG，等: "Potential protective effects of Clostridium butyricum on experimental gastric ulcers in mice", 《WORLD JOURNAL OF GASTROENTEROLOGY》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107095885A (en) * | 2017-04-28 | 2017-08-29 | 青岛东海药业有限公司 | Application of the clostridium butyricum in prevention or treatment COPD preparation is prepared |
| CN107115362A (en) * | 2017-04-28 | 2017-09-01 | 青岛东海药业有限公司 | Application of the bacillus coagulans in prevention or treatment bronchial astehma preparation is prepared |
| CN107137428A (en) * | 2017-06-05 | 2017-09-08 | 青岛东海药业有限公司 | Application of the clostridium butyricum in prevention or treatment chronic fatigue syndrome preparation is prepared |
| CN110592248A (en) * | 2019-10-25 | 2019-12-20 | 江南大学 | Method for efficiently identifying/screening clostridium butyricum and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110066753B (en) | Lactobacillus plantarum DP189 and application thereof | |
| CN104611273B (en) | Bacterial strains of clostridium butyricum UCN 12 and combinations thereof and application | |
| CN102827796B (en) | Lactobacillus plantarum with cadmium removing function and usage thereof | |
| CN106420840A (en) | Application of Clostridium butyricum in preparation of preparations for preventing or treating depression | |
| CN102533618A (en) | Lactobacillus plantarum CCFM8724 and application thereof | |
| CN106389479A (en) | Application of bacillus coagulans in preparing preparation for preventing or treating autism | |
| Bhamarapravati et al. | Antibacterial activity of Boesenbergia rotunda (L.) Mansf. and Myristica fragrans Houtt. against Helicobacter pylori | |
| CN105055457A (en) | Drug for preventing and treating alzheimer's disease as well as preparation method and application of drug | |
| CN103275893A (en) | Complex microbial inoculants of bifidobacterium longum and bifidobacterium animalis and preparation method of complex microbial inoculants | |
| CN105012350A (en) | Probiotic clostridium butyricum strain | |
| CN106957811B (en) | Format lactobacillus and Chinese medicine compound prescription with bacteriostasis and its application in treatment gynaecological imflammation | |
| CN105012349A (en) | Probiotic preparation for preventing and treating vascular dementia and preparation method of probiotic preparation | |
| US20230167402A1 (en) | Leuconostoc holzapfelii strain for preventing depilation improving hair growth or improving sexual disfuntion and composition comprising the same | |
| CN103565848B (en) | Application of bacillus coagulans in preparing preparations for preventing and treating helicobacter pylori infection | |
| CN104232535B (en) | Nocardia seriolae induced low virulent strain and application thereof | |
| CN106361777A (en) | Application of clostridium butyricum in preparation of preparation for preventing or treating autism | |
| CN105106244A (en) | Probiotics preparation for preventing and treating diabetic encephalopathy and method for preparing probiotics preparation | |
| CN107854495B (en) | Application of bacillus coagulans in preparation of preparation for reducing hematuria | |
| CN110090231A (en) | Application of the clostridium butyricum in preparation prevention or treatment cholangiocarcinoma preparation | |
| CN112852670A (en) | Bifidobacterium infantis DH231 and fermentation product, application and microecological preparation thereof | |
| US20210121538A1 (en) | Interactional Biosystem | |
| CN106890196A (en) | Application of the clostridium butyricum in prevention or treatment Parkinson's preparation is prepared | |
| Stringfellow et al. | Effect of bismuth citrate, lactose, and organic acid on necrotic enteritis in broilers | |
| CN104997812B (en) | The drug and its preparation method and application of anti-cerebral ischemia reperfusion injury | |
| CN107137428A (en) | Application of the clostridium butyricum in prevention or treatment chronic fatigue syndrome preparation is prepared |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170222 |
|
| RJ01 | Rejection of invention patent application after publication |